Report Detail

Other Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2019-2025

  • RnM3472137
  • |
  • 12 July, 2019
  • |
  • Global
  • |
  • 97 pages
  • |
  • QYResearch
  • |
  • Other

Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Vitamin E & Pioglitazone
      • 1.4.3 Ocaliva
      • 1.4.4 Elafibranor
      • 1.4.5 Selonsertib & Cenicriviroc
    • 1.5 Market by Application
      • 1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2014-2025)
      • 1.5.2 Hospital Pharmacy
      • 1.5.3 Online Provider
      • 1.5.4 Retail Pharmacy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Nonalcoholic Steatohepatitis (NASH) Market Size
    • 2.2 Nonalcoholic Steatohepatitis (NASH) Growth Trends by Regions
      • 2.2.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Regions (2014-2025)
      • 2.2.2 Nonalcoholic Steatohepatitis (NASH) Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Nonalcoholic Steatohepatitis (NASH) Market Size by Manufacturers
      • 3.1.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Nonalcoholic Steatohepatitis (NASH) Market Concentration Ratio (CR5 and HHI)
    • 3.2 Nonalcoholic Steatohepatitis (NASH) Key Players Head office and Area Served
    • 3.3 Key Players Nonalcoholic Steatohepatitis (NASH) Product/Solution/Service
    • 3.4 Date of Enter into Nonalcoholic Steatohepatitis (NASH) Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (2014-2019)
    • 4.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 5.2 Nonalcoholic Steatohepatitis (NASH) Key Players in United States
    • 5.3 United States Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 5.4 United States Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    6 Europe

    • 6.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 6.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Europe
    • 6.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 6.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    7 China

    • 7.1 China Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 7.2 Nonalcoholic Steatohepatitis (NASH) Key Players in China
    • 7.3 China Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 7.4 China Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    8 Japan

    • 8.1 Japan Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 8.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Japan
    • 8.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 8.4 Japan Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 9.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Southeast Asia
    • 9.3 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 9.4 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    10 India

    • 10.1 India Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 10.2 Nonalcoholic Steatohepatitis (NASH) Key Players in India
    • 10.3 India Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 10.4 India Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size (2014-2019)
    • 11.2 Nonalcoholic Steatohepatitis (NASH) Key Players in Central & South America
    • 11.3 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
    • 11.4 Central & South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application

    12 International Players Profiles

    • 12.1 Tobira Therapeutics
      • 12.1.1 Tobira Therapeutics Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.1.4 Tobira Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.1.5 Tobira Therapeutics Recent Development
    • 12.2 Cadila Healthcare
      • 12.2.1 Cadila Healthcare Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.2.4 Cadila Healthcare Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.2.5 Cadila Healthcare Recent Development
    • 12.3 Conatus Pharmaceuticals
      • 12.3.1 Conatus Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.3.4 Conatus Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.3.5 Conatus Pharmaceuticals Recent Development
    • 12.4 Galmed Pharmaceuticals
      • 12.4.1 Galmed Pharmaceuticals Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.4.4 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.4.5 Galmed Pharmaceuticals Recent Development
    • 12.5 Gemphire Therapeutics
      • 12.5.1 Gemphire Therapeutics Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.5.4 Gemphire Therapeutics Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.5.5 Gemphire Therapeutics Recent Development
    • 12.6 Genfit
      • 12.6.1 Genfit Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.6.4 Genfit Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.6.5 Genfit Recent Development
    • 12.7 Gilead Sciences
      • 12.7.1 Gilead Sciences Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.7.4 Gilead Sciences Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.7.5 Gilead Sciences Recent Development
    • 12.8 Intercept Pharmaceuticals
      • 12.8.1 Intercept Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.8.4 Intercept Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.8.5 Intercept Pharmaceuticals Recent Development
    • 12.9 Novartis International
      • 12.9.1 Novartis International Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.9.4 Novartis International Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.9.5 Novartis International Recent Development
    • 12.10 Shire
      • 12.10.1 Shire Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Nonalcoholic Steatohepatitis (NASH) Introduction
      • 12.10.4 Shire Revenue in Nonalcoholic Steatohepatitis (NASH) Business (2014-2019)
      • 12.10.5 Shire Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
      NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
      At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy.
      Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific.
      In 2018, the global Nonalcoholic Steatohepatitis (NASH) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.

      The key players covered in this study
      Tobira Therapeutics
      Cadila Healthcare
      Conatus Pharmaceuticals
      Galmed Pharmaceuticals
      Gemphire Therapeutics
      Genfit
      Gilead Sciences
      Intercept Pharmaceuticals
      Novartis International
      Shire

      Market segment by Type, the product can be split into
      Vitamin E & Pioglitazone
      Ocaliva
      Elafibranor
      Selonsertib & Cenicriviroc

      Market segment by Application, split into
      Hospital Pharmacy
      Online Provider
      Retail Pharmacy  

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Nonalcoholic Steatohepatitis (NASH) status, future forecast, growth opportunity, key market and key players.
      To present the Nonalcoholic Steatohepatitis (NASH) development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Nonalcoholic Steatohepatitis (NASH) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Nonalcoholic Steatohepatitis (NASH). Industry analysis & Market Report on Nonalcoholic Steatohepatitis (NASH) is a syndicated market report, published as Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Nonalcoholic Steatohepatitis (NASH) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,125.01
      4,687.52
      6,250.02
      3,471.71
      5,207.56
      6,943.42
      420,365.40
      630,548.10
      840,730.80
      268,573.11
      402,859.67
      537,146.22
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report